A gentler transplant for a hardened heart
For patients with advanced systemic sclerosis (SSc) and significant cardiac involvement, a reduced-intensity conditioning (RIC) regimen before autologous hematopoietic stem cell transplantation (AHSCT) offers a viable and potentially safer treatment pathway. A five-year follow-up study of 42 patients with SSc-related cardiac and pulmonary disease found a 75% overall survival rate, with key pre-transplant risk factors identified: the need for supplemental oxygen and elevated B-type natriuretic peptide (BNP) levels were strongly associated with higher mortality. This research provides crucial long-term data for risk-stratifying patients with this severe autoimmune condition, suggesting that RIC AHSCT can be a safe option, particularly for those without severe pre-existing oxygen dependency or markedly elevated cardiac stress biomarkers.
Upgrade and get 50% Off — Coupon: ERWMCWYU
Study Significance: This study directly informs cardio-rheumatology practice by providing concrete, long-term outcome data for a high-risk patient group. For clinicians managing systemic sclerosis, it clarifies which patients—specifically those not on oxygen with low BNP—are most likely to benefit from this intensive immunomodulatory therapy. It underscores the critical role of integrating cardiac biomarkers with clinical status for precision risk assessment in autoimmune-driven heart disease.
Source →Stay curious. Stay informed — with Science Briefing.
This is a one time Briefing, Upgrade to continue.
